Hepatitis E: the current state of play

Transfusion Medicine

Volumn 27, Issue 2, 2017, Pages 84-95

  Ankcorn, M J ^a,b   Tedder, R S ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEPATITIS; ANTIVIRAL RESISTANCE; BLOOD COMPONENT; BLOOD TRANSFUSION; CLINICAL FEATURE; DEVELOPED COUNTRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS E; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; NEUROLOGIC DISEASE; NONHUMAN; ORGAN; ORGAN TRANSPLANTATION; PERSISTENT INFECTION; PROPHYLAXIS; RELAPSE; REVIEW; RISK FACTOR; SEROPREVALENCE; TISSUES; VIROLOGY; VIRUS DIAGNOSIS; VIRUS TRANSMISSION; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; HEPATITIS E VIRUS; MEAT; PIG; SWINE DISEASES; TRANSMISSION; VETERINARY; ZOONOSES;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; MEAT PRODUCTS; SWINE; SWINE DISEASES; ZOONOSES;

EID: 85017180749     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/tme.12405     Document Type: Review

References (103)

1. Abravanel, F., Lhomme, S., Rostaing, L., Kamar, N. & Izopet, J. (2015) Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. Clinical Infectious Diseases, 60, 96–99.
2. Adlhoch, C., Avellon, A., Baylis, S.A. et al. (2016) Hepatitis E virus: assessment of the epidemiological situation in humans in Europe, 2014/15. Journal of Clinical Virology, 82, 9–16.
3. Andersson, M.I., Preiser, W., Maponga, T.G., Heys, I., Taljaard, J.J., van, Rensburg, C., Tedder, R.S. & Ijaz, S. (2013) Immune reconstitution hepatitis E: a neglected complication of antiretroviral therapy in Africa? AIDS, 27, 487–489.
4. Andonov, A., Rock, G., Lin, L., Borlang, J., Hooper, J., Grudeski, E. & Wu, J. (2014) Serological and molecular evidence of a plausible transmission of hepatitis E virus through pooled plasma. Vox Sanguinis, 107, 213–219.
5. Bauer, H., Luxembourger, C., Gottenberg, J.E. et al. (2015) Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study. Medicine (Baltimore), 94, e675.
6. Baylis, S.A., Gartner, T., Nick, S., Ovemyr, J. & Blumel, J. (2012) Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sanguinis, 103, 89–90.
7. Bazerbachi, F., Haffar, S., Garg, S.K. & Lake, J.R. (2016) Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature. Gastroenterology Report (Oxford), 4, 1–15.
8. Beale, M.A., Tettmar, K., Szypulska, R., Tedder, R.S. & Ijaz, S. (2011) Is there evidence of recent hepatitis E virus infection in English and North Welsh blood donors? Vox Sanguinis, 100, 340–342.
9. Behrendt, P., Luth, S., Dammermann, W. et al. (2015) Exacerbation of hepatitis E virus infection during anti-TNFalpha treatment. Journal of Viral Hepatitis, 22, 128.
10. Behrendt, P., Bremer, B., Todt, D., Brown, R.J., Heim, A., Manns, M.P., Steinmann, E. & Wedemeyer, H. (2016) Hepatitis E virus (HEV) ORF2 antigen levels differentiate between acute and chronic HEV infection. Journal of Infectious Diseases, 214, 361–368.
11. Bendall, R., Ellis, V., Ijaz, S., Ali, R. & Dalton, H. (2010) A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. Journal of Medical Virology, 82, 799–805.
12. Bettinger, D., Schorb, E., Huzly, D. et al. (2015) Chronic hepatitis E virus infection following allogeneic hematopoietic stem cell transplantation: an important differential diagnosis for graft versus host disease. Annals of Hematology, 94, 359–360.
13. Blasco-Perrin, H., Madden, R.G., Stanley, A. et al. (2015) Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study. Alimentary Pharmacology and Therapeutics, 42, 574–581.
14. Cao, D. & Meng, X.J. (2012) Molecular biology and replication of hepatitis E virus. Emerging Microbes & Infections, 1, e17.
15. Chaussade, H., Rigaud, E., Allix, A. et al. (2013) Hepatitis E virus seroprevalence and risk factors for individuals in working contact with animals. Journal of Clinical Virology, 58, 504–508.
16. Cleland, A., Smith, L., Crossan, C., Blatchford, O., Dalton, H.R., Scobie, L. & Petrik, J. (2013) Hepatitis E virus in Scottish blood donors. Vox Sanguinis, 105, 283–289.
17. Colson, P., Coze, C., Gallian, P., Henry, M., De Micco, P. & Tamalet, C. (2007) Transfusion-associated hepatitis E, France. Emerging Infectious Diseases, 13, 648–649.
18. Dalton, H.R., Fellows, H.J., Gane, E.J., Wong, P., Gerred, S., Schroeder, B., Croxson, M.C. & Garkavenko, O. (2007) Hepatitis E in New Zealand. Journal of Gastroenterology and Hepatology, 22, 1236–1240.
19. Dalton, H.R., Keane, F.E., Bendall, R., Mathew, J. & Ijaz, S. (2011) Treatment of chronic hepatitis E in a patient with HIV infection. Annals of Internal Medicine, 155, 479–480.
20. Dao Thi, V.L., Debing, Y., Neyts, J., Moradpour, D. & Gouttenoire, J. (2015) Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Journal of Hepatology, 62, S289–S290.
21. Debes, J.D., Pisano, M.B., Lotto, M. & Re, V. (2016) Hepatitis E virus infection in the HIV-positive patient. Journal of Clinical Virology, 80, 102–106.
22. Debing, Y., Emerson, S.U., Wang, Y., Pan, Q., Balzarini, J., Dallmeier, K. & Neyts, J. (2014) Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrobial Agents and Chemotherapy, 58, 267–273.
23. Debing, Y., Ramiere, C., Dallmeier, K. et al. (2016) Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. Journal of Hepatology, 65, 499–508.
24. Feagins, A.R., Opriessnig, T., Guenette, D.K., Halbur, P.G. & Meng, X.J. (2008) Inactivation of infectious hepatitis E virus present in commercial pig livers sold in local grocery stores in the United States. International Journal of Food Microbiology, 123, 32–37.
25. Fearon, M., Scalia, V., O'Brien, S.F. et al. (2014) Seroprevalence of Babesia and hepatitis E in Canadian blood donors. Transfusion, 54, 27A.
26. Feldt, T., Sarfo, F.S., Zoufaly, A. et al. (2013) Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon. Journal of Clinical Virology, 58, 18–23.
27. Feng, Z. & Lemon, S.M. (2014) Peek-a-boo: membrane hijacking and the pathogenesis of viral hepatitis. Trends in Microbiology, 22, 59–64.
28. Fischer, C., Hofmann, M., Danzer, M., Hofer, K., Kaar, J. & Gabriel, C. (2015) Seroprevalence and incidence of hepatitis E in blood donors in Upper Austria. PLoS One, 10, e0119576.
29. Gallian, P., Lhomme, S., Piquet, Y., Saune, K., Abravanel, F., Assal, A., Tiberghien, P. & Izopet, J. (2014) Hepatitis E virus infections in blood donors, France. Emerging Infectious Diseases, 20, 1914–1917.
30. Gauss, A., Wenzel, J.J., Flechtenmacher, C., Navid, M.H., Eisenbach, C., Jilg, W., Stremmel, W. & Schnitzler, P. (2012) Chronic hepatitis E virus infection in a patient with leukemia and elevated transaminases: a case report. Journal of Medical Case Reports, 6, 334.
31. Geng, Y., Zhang, H., Huang, W.T., J Harrison, T., Geng, K., Li, Z. & Wang, Y. (2014) Persistent hepatitis E virus genotype 4 infection in a child with acute lymphoblastic leukemia. Hepatitis Monthly, 14, e15618.
32. Gerolami, R., Borentain, P., Raissouni, F., Motte, A., Solas, C. & Colson, P. (2011) Treatment of severe acute hepatitis E by ribavirin. Journal of Clinical Virology, 52, 60–62.
33. Goyal, R., Kumar, A., Panda, S.K., Paul, S.B. & Acharya, S.K. (2012) Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. Antiviral Therapy, 17, 1091–1096.
34. Grewal, P., Kamili, S. & Motamed, D. (2014) Chronic hepatitis E in an immunocompetent patient: a case report. Hepatology, 59, 347–348.
35. Grierson, S., Heaney, J., Cheney, T. et al. (2015) Prevalence of hepatitis E virus infection in pigs at the time of slaughter, United Kingdom, 2013. Emerging Infectious Diseases, 21, 1396–1401.
36. Haffar, S., Bazerbachi, F., Garg, S., Lake, J.R. & Freeman, M.L. (2015) Frequency and prognosis of acute pancreatitis associated with acute hepatitis E: a systematic review. Pancreatology, 15, 321–326.
37. Hauser, L., Roque-Afonso, A.M., Beyloune, A. et al. (2014) Hepatitis E transmission by transfusion of intercept blood system-treated plasma. Blood, 123, 796–797.
38. Hewitt, P.E., Ijaz, S., Brailsford, S.R. et al. (2014) Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet, 384, 1766–1773.
39. Hogema, B.M., Molier, M., Slot, E. & Zaaijer, H.L. (2014) Past and present of hepatitis E in the Netherlands. Transfusion, 54, 3092–3096.
40. Hogema, B.M., Molier, M., Sjerps, M., de, Waal, M., van, Swieten, P., van de, Laar, T., Molenaar-de Backer, M. & Zaaijer, H.L. (2016) Incidence and duration of hepatitis E virus infection in Dutch blood donors. Transfusion, 56, 722–728.
41. Huzly, D., Umhau, M., Bettinger, D. et al. (2014) Transfusion-transmitted hepatitis E in Germany, 2013. Euro Surveillance, 19(21). pii: 20812.
42. Ijaz, S., Said, B., Boxall, E., Smit, E., Morgan, D. & Tedder, R.S. (2014) Indigenous hepatitis E in England and wales from 2003 to 2012: evidence of an emerging novel phylotype of viruses. Journal of Infectious Diseases, 209, 1212–1218.
43. Izopet, J., Labrique, A.B., Basnyat, B. et al. (2015) Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France. Journal of Clinical Virology, 70, 39–42.
44. Kamar, N., Selves, J., Mansuy, J.M. et al. (2008) Hepatitis E virus and chronic hepatitis in organ-transplant recipients. The New England Journal of Medicine, 358, 811–817.
45. Kamar, N., Abravanel, F., Selves, J. et al. (2010) Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation, 89, 353–360.
46. Kamar, N., Bendall, R.P., Peron, J.M. et al. (2011a) Hepatitis E virus and neurologic disorders. Emerging Infectious Diseases, 17, 173–179.
47. Kamar, N., Garrouste, C., Haagsma, E.B. et al. (2011b) Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology, 140, 1481–1489.
48. Kamar, N., Rostaing, L., Legrand-Abravanel, F. & Izopet, J. (2013) How should hepatitis E virus infection be defined in organ-transplant recipients? American Journal of Transplantation, 13, 1935–1936.
49. Kamar, N., Izopet, J., Tripon, S. et al. (2014) Ribavirin for chronic hepatitis E virus infection in transplant recipients. The New England Journal of Medicine, 370, 1111–1120.
50. Kamar, N., Lhomme, S., Abravanel, F. et al. (2015) An early viral response predicts the virological response to ribavirin in hepatitis E virus organ transplant patients. Transplantation, 99, 2124–2131.
51. Kamar, N., Lhomme, S., Abravanel, F., Marion, O., Peron, J.M., Alric, L. & Izopet, J. (2016) Treatment of HEV infection in patients with a solid-organ transplant and chronic hepatitis. Viruses, 8(8). pii: E222.
52. Khuroo, M.S. (2011) Discovery of hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Research, 161, 3–14.
53. Khuroo, M.S., Kamili, S. & Yattoo, G.N. (2004) Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area. Journal of Gastroenterology and Hepatology, 19, 778–784.
54. Koenecke, C., Pischke, S., Beutel, G., Ritter, U., Ganser, A., Wedemeyer, H. & Eder, M. (2014) Hepatitis E virus infection in a hematopoietic stem cell donor. Bone Marrow Transplantation, 49, 159–160.
55. Krain, L.J., Atwell, J.E., Nelson, K.E. & Labrique, A.B. (2014) Review article: fetal and neonatal health consequences of vertically transmitted hepatitis E virus infection. American Journal of Tropical Medicine and Hygiene, 90, 365–370.
56. Kumar Acharya, S., Kumar Sharma, P., Singh, R., Kumar Mohanty, S., Madan, K., Kumar Jha, J. & Kumar Panda, S. (2007) Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. Journal of Hepatology, 46, 387–394.
57. Lee, G.H., Tan, B.H., Teo, E.C. et al. (2015) Chronic infection with Camelid hepatitis E virus in a liver-transplant recipient who regularly consumes camel meat and milk. Gastroenterology, 150, 355–357.e3.
58. Lhomme, S., Dubois, M., Abravanel, F., Top, S., Bertagnoli, S., Guerin, J.L. & Izopet, J. (2013) Risk of zoonotic transmission of HEV from rabbits. Journal of Clinical Virology, 58, 357–362.
59. Lhomme, S., Kamar, N., Nicot, F. et al. (2016) Mutation in the hepatitis E virus polymerase and outcome of ribavirin therapy. Antimicrobial Agents and Chemotherapy, 60, 1608–1614.
60. Mansuy, J.M., Huynh, A., Abravanel, F., Recher, C., Peron, J.M. & Izopet, J. (2009) Molecular evidence of patient-to-patient transmission of hepatitis E virus in a hematology ward. Clinical Infectious Diseases, 48, 373–374.
61. Mansuy, J.M., Bendall, R., Legrand-Abravanel, F. et al. (2011) Hepatitis E virus antibodies in blood donors, France. Emerging Infectious Diseases, 17, 2309–2312.
62. Meng, X.J. (2013) Zoonotic and foodborne transmission of hepatitis E virus. Seminars in Liver Disease, 33, 41–49.
63. Meng, X.J., Purcell, R.H., Halbur, P.G. et al. (1997) A novel virus in swine is closely related to the human hepatitis E virus. Proceedings of the National Academy of Sciences of the United States of America, 94, 9860–9865.
64. Nelson, K.E. (2014) Transmission of hepatitis E virus by transfusion: what is the risk? Transfusion, 54, 8–10.
65. Neukam, K., Barreiro, P., Macias, J. et al. (2013) Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clinical Infectious Diseases, 57, 465–468.
66. Okamoto, H. (2013) Culture systems for hepatitis E virus. Journal of Gastroenterology, 48, 147–158.
67. Owada, T., Kaneko, M., Matsumoto, C. et al. (2014) Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system. Transfusion, 54, 2820–2827.
68. Pas, S.D., Streefkerk, R.H., Pronk, M., de, Man, R.A., Beersma, M.F., Osterhaus, A.D. & van der, Eijk, A.A. (2013) Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. Journal of Clinical Virology, 58, 629–634.
69. Péron, J.M., Abravanel, F., Guillaume, M. et al. (2016) Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. Liver International, 36, 328–333.
70. Peters van Ton, A.M., Gevers, T.J. & Drenth, J.P. (2015) Antiviral therapy in chronic hepatitis E: a systematic review. Journal of Viral Hepatitis, 22, 965–973.
71. Pischke, S., Stiefel, P., Franz, B. et al. (2012) Chronic hepatitis E in heart transplant recipients. American Journal of Transplantation, 12, 3128–3133.
72. Rivero-Juarez, A., Frias, M., Rodriguez-Cano, D., Cuenca-Lopez, F. & Rivero, A. (2016) Isolation of hepatitis E virus from breast milk during acute infection. Clinical Infectious Diseases, 62, 1464.
73. Robbins, A., Lambert, D., Ehrhard, F. et al. (2014) Severe acute hepatitis E in an HIV infected patient: successful treatment with ribavirin. Journal of Clinical Virology, 60, 422–423.
74. Roberts, S.S., Miller, R.K., Jones, J.K. et al. (2010) The ribavirin pregnancy registry: findings after 5 years of enrollment, 2003-2009. Birth Defects Research. Part A, Clinical and Molecular Teratology, 88, 551–559.
75. Said, B., Ijaz, S., Kafatos, G. et al. (2009) Hepatitis E outbreak on cruise ship. Emerging Infectious Diseases, 15, 1738–1744.
76. Said, B., Ijaz, S., Chand, M.A., Kafatos, G., Tedder, R. & Morgan, D. (2014) Hepatitis E virus in England and Wales: indigenous infection is associated with the consumption of processed pork products. Epidemiology and Infection, 142, 1467–1475.
77. Sauleda, S., Ong, E., Bes, M. et al. (2015) Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). Transfusion, 55, 972–979.
78. Schlosser, B., Stein, A., Neuhaus, R., Pahl, S., Ramez, B., Kruger, D.H., Berg, T. & Hofmann, J. (2012) Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. Journal of Hepatology, 56, 500–502.
79. Shrestha, A.C., Seed, C.R., Flower, R.L.P. et al. (2014) Hepatitis E virus and implications for blood supply safety, Australia. Emerging Infectious Diseases, 20, 1940–1942.
80. Slot, E., Hogema, B.M., Riezebos-Brilman, A., Kok, T.M., Molier, M. & Zaaijer, H.L. (2013) Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveillance, 18(31), pii: 20550.
81. Smith, D.B., Simmonds, P., Jameel, S. et al. (2014) Consensus proposals for classification of the family Hepeviridae. Journal of General Virology, 95, 2223–2232.
82. Stramer, S.L., Moritz, E.D., Foster, G.A. et al. (2016) Hepatitis E virus: seroprevalence and frequency of viral RNA detection among US blood donors. Transfusion, 56, 481–488.
83. Sultana, R. & Humayun, S. (2014) Fetomaternal outcome in acute hepatitis E. Journal of the College of Physicians and Surgeons–Pakistan, 24, 127–130.
84. Tabatabai, J., Wenzel, J.J., Soboletzki, M., Flux, C., Navid, M.H. & Schnitzler, P. (2014) First case report of an acute hepatitis E subgenotype 3c infection during pregnancy in Germany. Journal of Clinical Virology, 61, 170–172.
85. Tavitian, S., Peron, J.M., Huguet, F. et al. (2015) Ribavirin for chronic hepatitis prevention among patients with hematologic malignancies. Emerging Infectious Diseases, 21, 1466–1469.
86. Tedder, R.S., Tettmar, K.I., Brailsford, S.R. et al. (2016) Virology, serology, and demography of hepatitis E viremic blood donors in South East England. Transfusion, 56, 1529–1536.
87. Teo, C.G. (2012) Fatal outbreaks of jaundice in pregnancy and the epidemic history of hepatitis E. Epidemiology and Infection, 140, 767–787.
88. Teshale, E.H., Grytdal, S.P., Howard, C. et al. (2010) Evidence of person-to-person transmission of hepatitis E virus during a large outbreak in Northern Uganda. Clinical Infectious Diseases, 50, 1006–1010.
89. Thomas, D.L., Yarbough, P.O., Vlahov, D., Tsarev, S.A., Nelson, K.E., Saah, A.J. & Purcell, R.H. (1997) Seroreactivity to hepatitis E virus in areas where the disease is not endemic. Journal of Clinical Microbiology, 35, 1244–1247.
90. Todt, D., Gisa, A., Radonic, A. et al. (2016) In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut, 65, 1733–1743.
91. van der, Eijk, A.A., Pas, S.D., Cornelissen, J.J. & de, Man, R.A. (2014) Hepatitis E virus infection in hematopoietic stem cell transplant recipients. Current Opinion in Infectious Diseases, 27, 309–315.
92. Van Eijk, J.J.J., Madden, R.G., Van Der Eijk, A.A. et al. (2014) Neuralgic amyotrophy and hepatitis E virus infection. Neurology, 82, 498–503.
93. Versluis, J., Pas, S.D., Agteresch, H.J. et al. (2013) Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood, 122, 1079–1086.
94. Vollmer, T., Diekmann, J., Johne, R., Eberhardt, M., Knabbe, C. & Dreier, J. (2012) Novel approach for detection of hepatitis E virus infection in German blood donors. Journal of Clinical Microbiology, 50, 2708–2713.
95. Wang, Y., Van Der Laan, L.J.W., Man, R., Ruiter, P., Kwekkeboom, J., Peppelenbosch, M., Metselaar, H.J. & Pan, Q. (2013) Calcineurin inhibitors promote but mycophenolic acid inhibits hepatitis E virus infection in cell culture. Transplant International, 26, 227.
96. Wenzel, J.J., Preiss, J., Schemmerer, M., Huber, B. & Jilg, W. (2013) Test performance characteristics of anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. Journal of Infectious Diseases, 207, 497–500.
97. WHO (2016) World Health Organisation Fact Sheet. URL http://www.who.int/mediacentre/factsheets/fs280/en/ (Accessed 01/09/16).
98. Williams, T.P., Kasorndorkbua, C., Halbur, P.G., Haqshenas, G., Guenette, D.K., Toth, T.E. & Meng, X.J. (2001) Evidence of extrahepatic sites of replication of the hepatitis E virus in a swine model. Journal of Clinical Microbiology, 39, 3040–3046.
99. Wu, T., Zhu, F.C., Huang, S.J., Zhang, X.F., Wang, Z.Z., Zhang, J. & Xia, N.S. (2012) Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology, 55, 2038.
100. Xu, C., Wang, R.Y., Schechterly, C.A., Ge, S., Shih, J.W., Xia, N.S., Luban, N.L. & Alter, H.J. (2013) An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. Transfusion, 53, 2505–2511.
101. Zhang, J., Zhang, X.F., Huang, S.J. et al. (2015) Long-term efficacy of a hepatitis E vaccine. The New England Journal of Medicine, 372, 914–922.
102. Zhou, X., Wang, Y., Metselaar, H.J., Janssen, H.L.A., Peppelenbosch, M.P. & Pan, Q. (2014) Rapamycin and everolimus facilitate hepatitis e virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology, 61, 746–754.
103. Zhu, F.C., Zhang, J., Zhang, X.F. et al. (2010) Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet, 376, 895–902.